Molluscum contagiosum (MC) is a highly contagious skin infection caused by the MC poxvirus (MCV). Humans are the only host, and the disease affects 3-4 million US children, and up to 18% of children with HIV/AIDS. The lesions, which persist for 9 and up to 15 months, are painful, with a high propensity for autoinoculation and a critical acne-like emotional and social concern for adolescents. Unfortunately, no FDA approved treatment exists, which limits treatment options to in-office procedures including cauterization, cyro therapy and off-label drugs.
ViRAZE’s first product represents a $400 million market potential as a first and only treatment option for Molluscum Contagiosum.